ClinicalTrials.gg
CompletedNCT02907359Updated Aug 27, 2024Results posted

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

A Phase 3 interventional study of Guadecitabine and Treatment Choice in Myelodysplastic Syndromes and Leukemia, Myelomonocytic, Chronic, sponsored by Astex Pharmaceuticals, Inc.. Completed at 112 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd. — 5 open to participants now, 7 under way, 2 of them phase 3. Myelodysplastic Syndromes · Otsuka Holdings Co., Ltd..

Enrollment
Largest of 16
417 · median 70
Started
2017
the only one that year
Phase 3
4 of 17
none open now
Registered
4th of 17
by date

Among the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd., this one has the largest enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 3, and was the 4th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

5 of the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

A Phase 3, randomized, open-label, parallel-group, multicenter study designed to evaluate the efficacy and safety of guadecitabine in participants with MDS or CMML who failed or relapsed after adequate prior treatment with azacitidine, decitabine, or both. This global study will be conducted in approximately 15 countries. Approximately 408 participants from approximately 100 study centers will be randomly assigned in a 2:1 ratio to either guadecitabine (approximately 272 participants) or Treatment Choice (approximately 136 participants). The study consists of a 21-day screening period, a treatment period, a safety follow-up visit, and a long-term follow-up period. The study is expected to last more than 2 years, and the duration of individual participant participation will vary. Participants may continue to receive treatment for as long as they continue to benefit.

Read the detailed description

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs Treatment Choice (TC). Approximately 408 participants will be randomly assigned 2:1 to either guadecitabine or TC.

  • Guadecitabine: approximately 272 participants.
  • TC: approximately 136 participants.

Before randomization, the investigator will assign each participant to one of the following TC options:

  • Low dose cytarabine (LDAC).
  • Standard Intensive Chemotherapy (IC) of a 7+3 regimen.
  • Best Supportive Care (BSC) only. BSC will be provided to all participants as per standard and institutional practice. Participants randomized to TC will not be allowed to cross over to guadecitabine. Data will be reviewed by an independent Data Monitoring Committee at regular intervals, primarily to evaluate safety during study conduct. Randomization will be stratified by disease category (MDS vs CMML), bone marrow (BM) blasts (BM blasts >10% vs BM blasts ≤10%), TC option (LDAC vs IC vs BSC), and study center region.

Guadecitabine: 60 milligrams per square meter (mg/m\^2) given subcutaneously (SC) daily on Days 1-5 in 28-day cycles (delayed as needed to allow blood count recovery). Treatment should be given for at least 6 total cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy. Beyond 6 cycles, treatment should continue as long as the participant continues to benefit. BSC should be given according to standard and institutional practice.

Treatment Choice (TC): Before randomization, the investigator will assign each participant to one of the following TC options:

  • Low dose cytarabine (LDAC) given as 20 mg/m\^2 SC or intravenously (IV) once daily for 14 days in 28-day cycles (delayed as needed to allow blood count recovery). Treatment should be given for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
  • Standard Intensive Chemotherapy (IC) of a 7+3 regimen: given as cytarabine 100-200 mg/m\^2/day given as continuous infusion for 7 days and an anthracycline given as per institutional standard practice such as daunorubicin (45-60 mg/m\^2/day), or idarubicin (9-12 mg/m\^2/day), or mitoxantrone (8-12 mg/m\^2/day) by intravenous infusion for 3 days.
  • Best Supportive Care (BSC) only: given according to standard and institutional practice. BSC includes, but is not limited to blood transfusions (Red blood cells [RBCs] or platelets), growth factors including erythropoiesis stimulating agents (ESA), granulocyte stimulating factors (GSFs), iron chelating therapy, and broad-spectrum antibiotics and/or antifungals.
03

Conditions studied

  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants ≥18 years of age who are able to understand and comply with study procedures and provide written before any study-specific procedure.
  • or histologically confirmed diagnosis of MDS or CMML according to the 2008 World Health Organization (WHO) classification.
  • Performance status () of 0-2.
  • Previously treated MDS or CMML, defined as prior treatment with at least one hypomethylating agent (HMA; azacitidine and/or decitabine) for intermediate or high risk MDS or CMML whose disease progressed or as follows:

    1. Participant received HMA for at least 6 cycles and was still transfusion dependent.
    2. Participant received HMA for at least 2 complete cycles and had disease progression prior to Cycle 6 defined as

    i. ≥50% increase in bone marrow blasts from pre-HMA-treatment levels or from nadir post-HMA-treatment levels to >5% (for participants with pretreatment or nadir blasts ≤5%) or to >10% (for participants with pretreatment or nadir blasts >5%), and/or ii. Transfusion dependent and ≥2 gram/deciliter (g/dL) reduction of from pre-HMA-treatment levels.

Other prior treatments for MDS such as lenalidomide, cytarabine, intensive chemotherapy, hydroxyurea, erythropoietin and other growth factors, or hematopoietic cell transplant (HCT) are allowed.

  • Participants must have either:

    1. Bone marrow blasts >5% at randomization, OR
    2. Transfusion dependence, defined as having had transfusion (in the setting of active disease) of 2 or more units of RBC or within 8 weeks prior to randomization.
  • or ≥30 milliliter/minute (mL/min) estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology Collaboration).
  • Women of must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of childbearing potential and men with female partners of childbearing potential must agree to practice 2 highly effective measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment with guadecitabine and for at least 3 months after completing treatment and (b) while receiving treatment with LDAC or IC and for at least 6 months after completing treatment or for the duration specified in local prescribing information, whichever is longer.

Exclusion criteria

Exclusion Criteria:

  • Participants who have been diagnosed as having AML with peripheral blood or bone marrow blasts of ≥20%.
  • Participants who may still be sensitive to repeated treatment with decitabine or azacitidine such as participants who had response to prior decitabine or azacitidine treatment, but >6 months after stopping treatment with these agents.
  • Prior treatment with guadecitabine.
  • to decitabine, guadecitabine, or any of their .
  • Second currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
  • Treated with any drug within 2 weeks of the first dose of study treatment.
  • Total serum >2.5 × (ULN) (except for participants with Gilbert's Syndrome for whom direct bilirubin is \<2.5×ULN), or liver cirrhosis or chronic liver disease Class B or C.
  • Known active , , or infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
  • Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol.
  • Refractory congestive heart failure unresponsive to medical treatment, active infection resistant to all antibiotics, or advanced non-MDS associated pulmonary disease requiring >2 liters per minute oxygen.
  • of less than one month
  • Participants with TP53 mutations
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
417 participants (actual)

Study arms

  • Experimental
    Guadecitabine

    Participants received Guadecitabine 60 mg/m\^2, SC, on Days 1-5 of each 28-day cycle for at least 6 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy. Participants received Guadecitabine treatment beyond 6 cycles as long as the participant continued to benefit based on investigator judgment and participant response and tolerability (or up to a maximum of 36 cycles).

    Drug: Guadecitabine

  • Active comparator
    Treatment Choice

    Participants received one of the three treatment choice options: 1. LDAC 20 mg/m\^2 SC/IV once daily for 14 days of each 28-day cycles for at least 4 cycles in absence of disease progression or unacceptable toxicity.Participants who were responding or had stable disease were to continue treatment as per standard institutional practice. 2. Standard IC of a 7+3 regimen:Cytarabine 100-200 mg/m\^2/day given as continuous infusion for 7 days and anthracycline(daunorubicin(45-60 mg)/idarubicin(9-12 mg)/mitoxantrone(8-12 mg)/m\^2) by IV infusion for 3 days of each 28-day cycles. 3. BSC as needed during the treatment included,but was not limited to,blood transfusions(RBCs or platelets),growth factors including erythropoiesis stimulating agents,granulocyte stimulating factors,iron chelating therapy,and broad-spectrum antibiotics and/or antifungals. Duration for treatment choice was as per locally approved prescribing information and institutional standard practice or up to a maximum 30 cycles.

    Other: Treatment Choice

Interventions

  • Also known as: SGI-110

  • OtherTreatment Choice

    * BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals. * LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice. * Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the number of days from the day the participant was randomized to the date of death due to any cause. Survival time was censored on the last date the participant is known alive with no event of death. OS time will be estimated using the Kaplan-Meier method.

    Time frame: From randomization up to death (up to approximately 38.6 months)

Secondary outcomes

  1. Percentage of Participants With Transfusion Independence for Any 8 Consecutive Weeks

    Transfusion independence rate was calculated as the number of participants with neither RBC nor platelet transfusion for any period of 8 weeks after the initiation of treatment (or cycle 1 day 1 { C1D1} visit date for participants randomized to BSC or randomization date for participants not treated) and up to treatment discontinuation (or 180 days for participants discontinuing the treatment within 6 months), while maintaining haemoglobin (Hgb) ≥8 gram per deciliter (g/dL) and platelets ≥20×10\^9/liter (L) divided by the total number of participants included in the efficacy analysis. RBC or Platelet transfusion independence rate was defined similarly as above. Percentage of participants are rounded off to the single decimal point.

    Time frame: Up to approximately 46.6 months

  2. Percentage of Participants With Marrow Complete Response (mCR) Along With Transfusion Independence Rate

    mCR was defined as per 2006 Myelodysplastic Syndromes International Council for Harmonisation (MDS IWG) criteria as reduction of bone marrow (BM) blasts to ≤5% and decrease by 50% or more with or without normalization of peripheral counts. Transfusion independence rate was calculated as the number of participants with neither RBC nor platelet transfusion for any period of 8 weeks after the initiation of treatment (or C1D1 visit date for participants randomized to BSC or randomization date for participants not treated) and up to treatment discontinuation (or 180 days for participants discontinuing the treatment within 6 months), while maintaining Hgb ≥8 g/dL and platelets ≥20×10\^9/L divided by the total number of participants included in the efficacy analysis. The percentage of participants who achieved mCR and transfusion independence simultaneously in the same period were calculated for each group. Percentage of participants are rounded off to the single decimal point.

    Time frame: Up to approximately 46.6 months

  3. Survival Rate at 1 Year After Randomization

    One year survival rate was defined as the percentage of participants that survived at the end of the first year from randomization. Participants who did not have death in record were censored on the last date known to be alive. Percentage of participants are rounded off to the nearest whole number.

    Time frame: From randomization up to 12 months

  4. Leukemia-free Survival

    Leukemia-free survival was defined as the number of days from randomization to the earliest date when participants have bone marrow (BM) or peripheral blood (PB) blasts ≥20%, conversion to acute myeloid leukemia (AML) or death of any cause. Participants with no events in leukemia-free survival were censored on the last date of BM or PB blasts assessment, whichever is later. Survival time will be estimated using the Kaplan-Meier method.

    Time frame: From randomization up to 46.6 months

  5. Number of Days Alive and Out of the Hospital (NDAOH)

    The date of each hospital admission and discharge was collected for each participant for up to 6 months, unless the participant died or withdrew consent prior to that time. Duration of each hospital stay in days was calculated as date of discharge minus date of admission. The NDAOH within first 6 month period was calculated as: NDAOH 6M=180 -total duration of all hospital stays within 180 days from the first treatment -number of death days before Day 180. For participants who were lost to follow-up within 6 months, the NDAOH was calculated conservatively assuming that the participant would have died the day after the last contact day.

    Time frame: Up to 6 months

  6. Disease Response (DR) Rate

    DR: Complete Response(CR), Partial Response(PR),Marrow Complete Response(mCR), and Hematological Improvement(HI) including HI with Erythroid (HI-E), HI with Neutrophil (HI-N), or HI with Platelet (HI-P) based on IWG 2006 criteria. CR: BM:≤5% myeloblasts, Peripheral blood: Hgb≥11g/dL, Platelets(PLTs)≥100x10\^9/L, Neutrophils≥1.0x10\^9/L, Blasts 0%. PR: All CR criteria if abnormal before treatment except BM blasts decreased ≥50% over pretreatment but still\>5%, Cellularity, morphology not relevant. HI responses:1) HI-E: Hgb increase ≥1.5g/dL, Relevant reduction of RBC units transfusions by absolute ≥4 RBC transfusions/8 week(wk) compared with pretreatment transfusion number previous 8wk. Only RBC transfusions given for Hgb≤9.0g/dL. 2) HI-P: Absolute increase≥30x10\^9/L starting\>20x10\^9/L PLTs; Increase from\<20x10\^9/L to\>20x10\^9/L and by≥100%. 3) HI-N: ≥100% increase, absolute increase\>0.5x10\^9/L.

    Time frame: Up to approximately 46.6 months

  7. Duration of Complete Response (CR)

    Duration of complete response (in number of days) was calculated from the first time a CR was observed to the date of the earliest of the following three events: 1) relapse/disease progression, 2) start of alternative therapy (except Hematopoietic Cell Transplant \[HCT\]) or 3) death. In the absence of any event, the duration of CR was censored at the last available time point (BM assessment, PB assessment, or safety/long-term follow-up visit) at which an event was not observed. Duration of complete response was analysed using a Kaplan-Meier method for participants who achieved a CR during the study. CR: BM: ≤5% myeloblasts (all cell lines normal maturation), Peripheral blood: Hgb ≥11g/dL, PLTs ≥100x10\^9/L, Neutrophils ≥1.0x10\^9/L, Blasts 0%.

    Time frame: Up to approximately 46.6 months

  8. Time to First Response, Complete Response (CR) and Best Response

    Time to first response was the time(days) from randomization to first date when any response was achieved. Time to CR was the time(days) from randomization to first date when CR was achieved. Time to best response was the time(days) from randomization to first date when participant's best response (CR,PR,mCR or HI) was achieved. CR:BM:≤5% myeloblasts, Peripheral blood:Hgb≥11g/dL,PLTs≥100x10\^9/L,Neutrophils≥1.0x10\^9/L,Blasts 0%. PR: All CR criteria except BM blasts decreased≥50% over pretreatment but still \>5%,Cellularity,morphology not relevant. mCR: Reduction of BM blasts to≤5%; decrease ≥50% with/without normalization of peripheral counts. HI responses:1)HI-E:Hgb increase≥1.5 g/dL, Relevant reduction of RBC units transfusions by absolute≥4 RBC transfusions/8wk compared with pretreatment transfusion number previous 8wk. 2)HI-P:Absolute increase≥30x10\^9/L starting\>20x10\^9/L PLTs; Increase from≤20 to\>20x10\^9/L and by≥100% 3)HI-N:≥100% granulocyte increase, absolute increase\>0.5x10\^9/L.

    Time frame: From study Day 1 to the earliest date that a response was first documented (up to approximately 46.6 months)

  9. Number of Red Blood Cell (RBC) and Platelet Transfusions

    The total number of RBCs transfused or, separately, the total number of platelets transfused up to the 6-month time point for each participant was counted from the date of randomization to Day 180, the date of last contact, or date of death, whichever occurred earlier. One RBC or platelet transfusion was defined as one unit, and a single bag of RBCs or platelets was considered one unit. The mean total number of RBC or platelet units transfused per participant is presented.

    Time frame: Up to 6 months

  10. Change From Baseline in Health-related Quality of Life (QOL) By EuroQol 5-level 5-dimension (EQ-5D-5L) Summary Index

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L, first component is a descriptive system five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a second component visual analogue scale (VAS) that measures health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. The health status is converted to an index value using the country-specific weighted scoring algorithm for England. The summary index value for the England ranges from a worst score of -0.281 to a best score of 1. An increase in the EQ-5D-5L total score indicates improvement.

    Time frame: Baseline to Month 6

  11. Change From Baseline in Health-related QOL: EuroQOL Visual Analogue Scale (EQ-VAS) Score

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. The second component, EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

    Time frame: Baseline to Month 6

  12. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization; results in persistent or significant disability; is congenital anomaly; is suspected transmission of any infectious agent via a medicinal product or is medically important. Treatment emergent AEs which are those with onset date on or after the date of the first dose of study drug on C1D1 until 30 days after the last dose of study treatment, or the start of an alternative anticancer treatment, whichever occurs first.

    Time frame: From first dose through end of study (up to approximately 46.6 months)

  13. 30-day and 60-day All-cause Mortality

    Number of deaths, regardless of cause, within 30 or 60 days from the first study dose divided by the total number of participants included in the Safety Analysis Set. Participants who died within 30 days were also included in the 60-day mortality calculations.

    Time frame: From first dose until 60 days after study treatment initiation

07

Results

Posted May 18, 2023

Participant flow

Participants took part in the study at 101 investigative sites in the United States, Canada, Spain, Italy, France, Germany, Czech Republic, Denmark, Poland, Belgium, Sweden, United Kingdom, Japan, and South Korea from 13 January 2017 to 30 November 2020.

Participant flow — Overall Study
MilestoneGuadecitabineTreatment Choice
Started277140
Safety analysis set270122
Completed3612
Not completed241128
Withdrew: Death234117
Withdrew: Withdrawal by subject611
Withdrew: Lost to follow-up10

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the number of days from the day the participant was randomized to the date of death due to any cause. Survival time was censored on the last date the participant is known alive with no event of death. OS time will be estimated using the Kaplan-Meier method.

Time frame:
From randomization up to death (up to approximately 38.6 months)
Reported as:
Median · days
Overall Survival (OS)
daysGuadecitabineTreatment Choice
Overall Survival (OS)277.0 (243.0 to 313.0)252.0 (200.0 to 325.0)
Statistical analysis
  • Guadecitabine vs Treatment Choice · Stratified Log-rank test · p = 0.6063 (OS between Guadecitabine vs Treatment Choice using stratified log-rank test. Due to pre-specified hierarchical testing plan, other endpoints were not evaluated for statistical significance.) · Hazard ratio (hr): 0.94 · 95% CI 0.74 to 1.19
SecondaryPercentage of Participants With Transfusion Independence for Any 8 Consecutive Weeks

Transfusion independence rate was calculated as the number of participants with neither RBC nor platelet transfusion for any period of 8 weeks after the initiation of treatment (or cycle 1 day 1 { C1D1} visit date for participants randomized to BSC or randomization date for participants not treated) and up to treatment discontinuation (or 180 days for participants discontinuing the treatment within 6 months), while maintaining haemoglobin (Hgb) ≥8 gram per deciliter (g/dL) and platelets ≥20×10\^9/liter (L) divided by the total number of participants included in the efficacy analysis. RBC or Platelet transfusion independence rate was defined similarly as above. Percentage of participants are rounded off to the single decimal point.

Time frame:
Up to approximately 46.6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Transfusion Independence for Any 8 Consecutive Weeks
percentage of participantsGuadecitabineTreatment Choice
Transfusion Independence Rate (8 weeks)15.915.7
Platelet Transfusion Independence Rate32.137.9
RBC Transfusion Independence Rate22.422.0
SecondaryPercentage of Participants With Marrow Complete Response (mCR) Along With Transfusion Independence Rate

mCR was defined as per 2006 Myelodysplastic Syndromes International Council for Harmonisation (MDS IWG) criteria as reduction of bone marrow (BM) blasts to ≤5% and decrease by 50% or more with or without normalization of peripheral counts. Transfusion independence rate was calculated as the number of participants with neither RBC nor platelet transfusion for any period of 8 weeks after the initiation of treatment (or C1D1 visit date for participants randomized to BSC or randomization date for participants not treated) and up to treatment discontinuation (or 180 days for participants discontinuing the treatment within 6 months), while maintaining Hgb ≥8 g/dL and platelets ≥20×10\^9/L divided by the total number of participants included in the efficacy analysis. The percentage of participants who achieved mCR and transfusion independence simultaneously in the same period were calculated for each group. Percentage of participants are rounded off to the single decimal point.

Time frame:
Up to approximately 46.6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Marrow Complete Response (mCR) Along With Transfusion Independence Rate
percentage of participantsGuadecitabineTreatment Choice
Percentage of Participants With Marrow Complete Response (mCR) Along With Transfusion Independence Rate5.82.9
SecondarySurvival Rate at 1 Year After Randomization

One year survival rate was defined as the percentage of participants that survived at the end of the first year from randomization. Participants who did not have death in record were censored on the last date known to be alive. Percentage of participants are rounded off to the nearest whole number.

Time frame:
From randomization up to 12 months
Reported as:
Number · percentage of participants
Survival Rate at 1 Year After Randomization
percentage of participantsGuadecitabineTreatment Choice
Survival Rate at 1 Year After Randomization39 (34 to 45)39 (30 to 47)
SecondaryLeukemia-free Survival

Leukemia-free survival was defined as the number of days from randomization to the earliest date when participants have bone marrow (BM) or peripheral blood (PB) blasts ≥20%, conversion to acute myeloid leukemia (AML) or death of any cause. Participants with no events in leukemia-free survival were censored on the last date of BM or PB blasts assessment, whichever is later. Survival time will be estimated using the Kaplan-Meier method.

Time frame:
From randomization up to 46.6 months
Reported as:
Median · days
Leukemia-free Survival
daysGuadecitabineTreatment Choice
Leukemia-free Survival173.0 (135.0 to 206.0)181.0 (125.0 to 213.0)
SecondaryNumber of Days Alive and Out of the Hospital (NDAOH)

The date of each hospital admission and discharge was collected for each participant for up to 6 months, unless the participant died or withdrew consent prior to that time. Duration of each hospital stay in days was calculated as date of discharge minus date of admission. The NDAOH within first 6 month period was calculated as: NDAOH 6M=180 -total duration of all hospital stays within 180 days from the first treatment -number of death days before Day 180. For participants who were lost to follow-up within 6 months, the NDAOH was calculated conservatively assuming that the participant would have died the day after the last contact day.

Time frame:
Up to 6 months
Reported as:
Median · days
Number of Days Alive and Out of the Hospital (NDAOH)
daysGuadecitabineTreatment Choice
Number of Days Alive and Out of the Hospital (NDAOH)144.0 (0 to 180)149.5 (0 to 180)
SecondaryDisease Response (DR) Rate

DR: Complete Response(CR), Partial Response(PR),Marrow Complete Response(mCR), and Hematological Improvement(HI) including HI with Erythroid (HI-E), HI with Neutrophil (HI-N), or HI with Platelet (HI-P) based on IWG 2006 criteria. CR: BM:≤5% myeloblasts, Peripheral blood: Hgb≥11g/dL, Platelets(PLTs)≥100x10\^9/L, Neutrophils≥1.0x10\^9/L, Blasts 0%. PR: All CR criteria if abnormal before treatment except BM blasts decreased ≥50% over pretreatment but still\>5%, Cellularity, morphology not relevant. HI responses:1) HI-E: Hgb increase ≥1.5g/dL, Relevant reduction of RBC units transfusions by absolute ≥4 RBC transfusions/8 week(wk) compared with pretreatment transfusion number previous 8wk. Only RBC transfusions given for Hgb≤9.0g/dL. 2) HI-P: Absolute increase≥30x10\^9/L starting\>20x10\^9/L PLTs; Increase from\<20x10\^9/L to\>20x10\^9/L and by≥100%. 3) HI-N: ≥100% increase, absolute increase\>0.5x10\^9/L.

Time frame:
Up to approximately 46.6 months
Reported as:
Number · percentage of participants
Disease Response (DR) Rate
percentage of participantsGuadecitabineTreatment Choice
Complete Response (CR)1.4 (0.0 to 2.8)0.7 (0.0 to 2.1)
Partial Response (PR)0 (0 to 0)0 (0 to 0)
Marrow Complete Response (mCR)17.3 (12.9 to 21.8)8.6 (3.9 to 13.2)
Hematological Improvement (HI)3.2 (1.2 to 5.3)5.7 (1.9 to 9.6)
HI with Erythroid (HI-E)1.1 (0.0 to 2.2)2.1 (0.0 to 4.5)
HI with Platelet (HI-P)1.8 (0.2 to 3.3)2.1 (0.0 to 4.5)
HI with Neutrophil (HI-N)0.7 (0.0 to 1.7)2.1 (0.0 to 4.5)
SecondaryDuration of Complete Response (CR)

Duration of complete response (in number of days) was calculated from the first time a CR was observed to the date of the earliest of the following three events: 1) relapse/disease progression, 2) start of alternative therapy (except Hematopoietic Cell Transplant \[HCT\]) or 3) death. In the absence of any event, the duration of CR was censored at the last available time point (BM assessment, PB assessment, or safety/long-term follow-up visit) at which an event was not observed. Duration of complete response was analysed using a Kaplan-Meier method for participants who achieved a CR during the study. CR: BM: ≤5% myeloblasts (all cell lines normal maturation), Peripheral blood: Hgb ≥11g/dL, PLTs ≥100x10\^9/L, Neutrophils ≥1.0x10\^9/L, Blasts 0%.

Time frame:
Up to approximately 46.6 months
Reported as:
Median · days
Duration of Complete Response (CR)
daysGuadecitabineTreatment Choice
Duration of Complete Response (CR)198 (112.0 to 266.0)406 (NA to NA)
SecondaryTime to First Response, Complete Response (CR) and Best Response

Time to first response was the time(days) from randomization to first date when any response was achieved. Time to CR was the time(days) from randomization to first date when CR was achieved. Time to best response was the time(days) from randomization to first date when participant's best response (CR,PR,mCR or HI) was achieved. CR:BM:≤5% myeloblasts, Peripheral blood:Hgb≥11g/dL,PLTs≥100x10\^9/L,Neutrophils≥1.0x10\^9/L,Blasts 0%. PR: All CR criteria except BM blasts decreased≥50% over pretreatment but still \>5%,Cellularity,morphology not relevant. mCR: Reduction of BM blasts to≤5%; decrease ≥50% with/without normalization of peripheral counts. HI responses:1)HI-E:Hgb increase≥1.5 g/dL, Relevant reduction of RBC units transfusions by absolute≥4 RBC transfusions/8wk compared with pretreatment transfusion number previous 8wk. 2)HI-P:Absolute increase≥30x10\^9/L starting\>20x10\^9/L PLTs; Increase from≤20 to\>20x10\^9/L and by≥100% 3)HI-N:≥100% granulocyte increase, absolute increase\>0.5x10\^9/L.

Time frame:
From study Day 1 to the earliest date that a response was first documented (up to approximately 46.6 months)
Reported as:
Median · days
Time to First Response, Complete Response (CR) and Best Response
daysGuadecitabineTreatment Choice
Time to First Response (CR, PR, mCR, or HI)63.0 (28 to 323)67.0 (21 to 295)
Time to CR91.0 (56 to 106)266.0 (266.0 to 266.0)
Time to Best Response (CR, PR, mCR, or HI)64.0 (28 to 469)77.0 (23 to 295)
SecondaryNumber of Red Blood Cell (RBC) and Platelet Transfusions

The total number of RBCs transfused or, separately, the total number of platelets transfused up to the 6-month time point for each participant was counted from the date of randomization to Day 180, the date of last contact, or date of death, whichever occurred earlier. One RBC or platelet transfusion was defined as one unit, and a single bag of RBCs or platelets was considered one unit. The mean total number of RBC or platelet units transfused per participant is presented.

Time frame:
Up to 6 months
Reported as:
Mean · units of transfused RBC or platelet
Number of Red Blood Cell (RBC) and Platelet Transfusions
units of transfused RBC or plateletGuadecitabineTreatment Choice
RBC Transfusions18.9 ± 13.9415.0 ± 13.53
Platelet Transfusions16.8 ± 18.6412.1 ± 20.15
SecondaryChange From Baseline in Health-related Quality of Life (QOL) By EuroQol 5-level 5-dimension (EQ-5D-5L) Summary Index

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L, first component is a descriptive system five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a second component visual analogue scale (VAS) that measures health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. The health status is converted to an index value using the country-specific weighted scoring algorithm for England. The summary index value for the England ranges from a worst score of -0.281 to a best score of 1. An increase in the EQ-5D-5L total score indicates improvement.

Time frame:
Baseline to Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Health-related Quality of Life (QOL) By EuroQol 5-level 5-dimension (EQ-5D-5L) Summary Index
score on a scaleGuadecitabineTreatment Choice
Baseline0.8414 ± 0.15960.8404 ± 0.1587
Change from Baseline at Month 6-0.0386 ± 0.1466-0.0149 ± 0.1266
SecondaryChange From Baseline in Health-related QOL: EuroQOL Visual Analogue Scale (EQ-VAS) Score

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. The second component, EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

Time frame:
Baseline to Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Health-related QOL: EuroQOL Visual Analogue Scale (EQ-VAS) Score
score on a scaleGuadecitabineTreatment Choice
Baseline71.24 ± 18.3370.70 ± 18.32
Change from Baseline at Month 6-1.52 ± 16.39-2.43 ± 18.04
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization; results in persistent or significant disability; is congenital anomaly; is suspected transmission of any infectious agent via a medicinal product or is medically important. Treatment emergent AEs which are those with onset date on or after the date of the first dose of study drug on C1D1 until 30 days after the last dose of study treatment, or the start of an alternative anticancer treatment, whichever occurs first.

Time frame:
From first dose through end of study (up to approximately 46.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsGuadecitabineTreatment Choice
TEAE268113
SAE21665
Secondary30-day and 60-day All-cause Mortality

Number of deaths, regardless of cause, within 30 or 60 days from the first study dose divided by the total number of participants included in the Safety Analysis Set. Participants who died within 30 days were also included in the 60-day mortality calculations.

Time frame:
From first dose until 60 days after study treatment initiation
Reported as:
Count of participants · Participants
30-day and 60-day All-cause Mortality
ParticipantsGuadecitabineTreatment Choice
Within 30 Days166
Within 60 days3513

Adverse events

Collected over From first dose through end of study (up to approximately 46.6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Guadecitabine237/277 (85.6%)216/270 (80%)266/270 (98.5%)
Treatment Choice122/140 (87.1%)65/122 (53.3%)107/122 (87.7%)
Most frequent serious events
Showing 10 of 202
Most frequent serious events
EventGuadecitabineTreatment Choice
Febrile NeutropeniaBlood and lymphatic system disorders80/27019/122
PneumoniaInfections and infestations72/27017/122
SepsisInfections and infestations26/2704/122
Septic ShockInfections and infestations16/2702/122
CellulitisInfections and infestations14/2702/122
BacteraemiaInfections and infestations11/2701/122
ThrombocytopeniaBlood and lymphatic system disorders8/2702/122
AnaemiaBlood and lymphatic system disorders7/2702/122
PyrexiaGeneral disorders7/2702/122
General Physical Health DeteriorationGeneral disorders3/2703/122
Most frequent other events
Showing 10 of 50
Most frequent other events
EventGuadecitabineTreatment Choice
NeutropeniaBlood and lymphatic system disorders92/27019/122
ThrombocytopeniaBlood and lymphatic system disorders84/27025/122
AnaemiaBlood and lymphatic system disorders63/27022/122
ConstipationGastrointestinal disorders62/27012/122
DiarrhoeaGastrointestinal disorders60/27020/122
PyrexiaGeneral disorders60/27024/122
FatigueGeneral disorders59/27011/122
AstheniaGeneral disorders53/27012/122
Decreased AppetiteMetabolism and nutrition disorders49/2705/122
EpistaxisRespiratory, thoracic and mediastinal disorders44/27021/122

Baseline characteristics

The Efficacy Analysis Set included all participants randomly assigned to the study treatment.

Age, Continuous
Age, Continuous(years)GuadecitabineTreatment ChoiceTotal
Mean73.5 ± 773.7 ± 6.173.6 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)GuadecitabineTreatment ChoiceTotal
Female8344127
Male19496290
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GuadecitabineTreatment ChoiceTotal
Hispanic or Latino24731
Not Hispanic or Latino225117342
Unknown or Not Reported281644
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GuadecitabineTreatment ChoiceTotal
American Indian or Alaska Native011
Asian643397
Native Hawaiian or Other Pacific Islander011
Black or African American538
White17986265
More than one race000
Unknown or Not Reported291645
08

Study locations

112 sites
  • City of Hope
    Duarte, California 91010, United States
  • Desert Hematology Oncology Medical Group, Inc.
    Rancho Mirage, California 92270, United States
  • Cancer Specialists of North Florida
    Fleming Island, Florida 32003, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • North Shore Medical Center
    Evanston, Illinois 60201, United States
  • Franciscan Health Indianapolis
    Indianapolis, Indiana 46237, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • University of Michigan Cancer Center
    Ann Arbor, Michigan 48109, United States
  • John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Duke Cancer Center
    Durham, North Carolina 27705, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Bon Secours Saint Francis Hospital
    Greenville, South Carolina 29607, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • West Virginia University Mary Babb Randolph Cancer Center
    Morgantown, West Virginia 26506, United States
  • Ziekenhuis Netwerk Antwerpen Stuivenberg
    Antwerp, Belgium
  • Algemeen Ziekenhuis Sint-Jan Brugge-Oostende
    Brugge, Belgium
  • Grand Hôpital de Charleroi - Notre Dame
    Charleroi, Belgium
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Royal Victoria Regional Health Centre
    Barrie, Ontario L4M 6M2, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 1C3, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2C1, Canada
  • Burnaby Hospital
    Burnaby, Canada
  • Moncton Hospital
    Moncton, Canada
  • Maisonneuve-Rosemont Hôpital Service d'Hematologie et d'Oncologie Medicale
    Montréal, Canada
  • Saskatchewan Cancer Agency
    Regina, Canada
  • Fakultní nemocnice Brno
    Brno, Czechia
  • Fakultni Nemocnice Hradec Králové
    Hradec Králové, Czechia
  • Fakultní nemocnice Ostrava
    Ostrava, Czechia
  • Onkologická klinika Všeobecná fakultní nemocnice v Praze a 1
    Praha 2, Czechia
  • Fakultní Nemocnice Královské Vinohrady
    Praha, Czechia
  • Aalborg Universitetshospital
    Aalborg, Denmark
  • Aarhus Universitetshospital
    Aarhus, Denmark
  • Rigshospitalet
    Copenhagen, Denmark
  • Odense University Hospital
    Odense, Denmark
  • Centre Hospitalier Universitaire
    La Tronche, France
  • Hôpital Dupuytren
    Limoges, France
  • GHR Mulhouse Sud-Alsace
    Mulhouse Cedex, France
  • Hôpital Hôtel-Dieu
    Nantes, France
  • Centre Antoine Lacassagne
    Nice, France
  • Hôpital Saint Louis
    Paris, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, France
  • Centre Hospitalier Universitaire de Toulouse
    Toulouse, France
  • Städtisches Klinikum Braunschweig
    Braunschweig, Germany
  • Marien Hospital Düsseldorf
    Düsseldorf, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, Germany
  • Universitätsklinikum Halle
    Halle, Germany
  • Universitätsklinikum Ulm
    Ulm, Germany
  • Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria
    Alessandria, Italy
  • Azienda Ospedaliero Universitaria Careggi
    Firenze, Italy
  • Azienda Ospedaliera Universitaria San Martino
    Genova, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Italy
  • AORN A. Cardarelli
    Napoli, Italy
  • Azienda Ospedaliera Universitaria-Maggiore della Carità di Novara
    Novara, Italy
  • Azienda Ospedaliera Ospedali Riuniti Marche Nord
    Pesaro, Italy
  • Ospedale S. Eugenio
    Roma, Italy
  • NHO Nagoya Medical Center
    Nagoya-shi, Aichi, Japan
  • Narita Red Cross Hospital
    Narita, Chiba, Japan
  • University of Fukui Hospital
    Yoshida, Fukui, Japan
  • Chugoku Central Hospital
    Fukuyama-shi, Hiroshima, Japan
  • Tokai University Hospital
    Isehara, Kanagawa, Japan
  • Kitasato University Hospital
    Sagamihara-shi, Kanagawa, Japan
  • Yokohama Municipal Citizen's Hospital
    Yokohama, Kanagawa, Japan
  • Nagasaki University Hospital
    Nagasaki, Nagasaki-shi, Japan
  • Kansai Medical University Hirakata
    Hirakata, Osaka, Japan
  • Kindai University Hospital
    Osakasayama-shi, Osaka, Japan
  • Saitama Medical Center
    Kawagoe, Saitama, Japan
  • Nippon Medical School Hospital
    Bunkyō-Ku, Tokyo, Japan
  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Koto, Tokyo, Japan
  • NTT Medical Center Tokyo
    Shinagawa, Tokyo, Japan
  • National Hospital Organization Disaster Medical Center
    Tachikawa, Tokyo, Japan
  • National Hospital Organization Kyushu
    Fukuoka, Japan
  • Fukushima Medical University
    Fukushima, Japan
  • Gifu Municipal Hospital
    Gifu, Japan
  • National Hospital Organization Kumamoto Medical Center
    Kumamoto, Japan
  • Japanese Red Cross Kyoto Daini Hospital
    Kyoto, Japan
  • University Hospital-Kyoto Prefectural University of Medicine
    Kyoto, Japan
  • Yamagata University Hospital
    Yamagata, Japan
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Seoul Saint Mary's Hospital
    Seoul, 137-701, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, 44033, Korea, Republic of
  • Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
    Lublin, Poland
  • Instytut Hematologii i Transfuzjologii
    Warszawa, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny
    Warszawa, Poland
  • Hospital General Universitario de Alicante
    Alicante, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Spain
  • Fundació Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, Spain
  • Hospital San Pedro de Alcantara
    Cáceres, Spain

Showing the first 100 of 112 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Mar 2020, 38 months.

Results were first posted in May 2023, 3 years 1 month after primary completion. A results delay was requested in Mar 2021.

Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 38 months is close to that.

Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2016
First posted
Sep 20, 2016
StartActual
Jan 13, 2017
Primary completionActual
Mar 31, 2020
CompletionActual
Nov 30, 2020
Results delay requested
Mar 29, 2021
Results first posted
May 18, 2023
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02907359
Responsible party
Sponsor
First posted
Sep 20, 2016
Start date
Jan 13, 2017
Primary completion
Mar 31, 2020
Completion
Nov 30, 2020
Results posted
May 18, 2023
Last update
Aug 27, 2024

Study contacts

Yuri Sano, MD, PhD
study director · Astex Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guadecitabine

Start the discussion